Christian Selmer1, Jonas Bjerring Olesen, Morten Lock Hansen, Lene Mia von Kappelgaard, Jesper Clausager Madsen, Peter Riis Hansen, Ole Dyg Pedersen, Jens Faber, Christian Torp-Pedersen, Gunnar Hilmar Gislason. 1. Department of Cardiology (C.S., J.B.O., M.L.H., P.R.H., G.H.G.), Gentofte University Hospital, DK-2900 Hellerup, Denmark; Department of Endocrinology (C.S., J.F.), Herlev University Hospital, DK-2730 Herlev, Denmark; Copenhagen General Practitioners Laboratory (J.C.M.), DK-2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences (J.F., G.H.G.), University of Copenhagen, DK-2200 Copenhagen, Denmark; Department of Cardiology (O.D.P.), Roskilde University Hospital, DK-4000 Roskilde, Denmark; Institute of Health, Science, and Technology (C.T.-P.), Aalborg University, DK-9220 Aalborg, Denmark; and National Institute of Public Health (L.M.v.K., G.H.G.), University of Southern Denmark, DK-1353 Copenhagen, Denmark.
Abstract
CONTEXT: Thyroid dysfunction has been associated with both increased all-cause and cardiovascular mortality, but limited data are available on mild thyroid dysfunction and cause-specific mortality. OBJECTIVE: The objective of the study was to examine the risk of all-cause mortality, major adverse cardiovascular events (MACEs), and cause-specific events in subjects with overt and subclinical thyroid dysfunction. DESIGN: This was a retrospective cohort study. SETTING AND PARTICIPANTS: Participants in the study were subjects who underwent thyroid blood tests, without prior thyroid disease, consulting their general practitioner in 2000-2009 in Copenhagen, Denmark. MAIN OUTCOME MEASURE: All-cause mortality, MACEs, and cause-specific events identified in nationwide registries were measured. RESULTS: A total of 47 327 (8.4%) deaths occurred among 563 700 included subjects [mean age 48.6 (SD ± 18.2) y; 39% males]. All-cause mortality was increased in overt and subclinical hyperthyroidism [age adjusted incidence rates of 16 and 15 per 1000 person-years, respectively; incidence rate ratios (IRRs) 1.25 [95% confidence interval (CI) 1.15-1.36] and 1.23 (95% CI 1.16-1.30)] compared with euthyroid (incidence rate of 12 per 1000 person-years). Risk of MACEs was elevated in overt and subclinical hyperthyroidism [IRRs 1.16 (95% CI 1.05-1.27) and 1.09 (95% CI 1.02-1.16)] driven by heart failure [IRRs 1.14 (95% CI 0.99-1.32) and 1.20 (95% CI 1.10-1.31)]. A reduction of all-cause mortality was observed in subclinical hypothyroidism with TSH of 5-10 mIU/L [IRR 0.92 (95% CI 0.86-0.98)]. CONCLUSIONS: Heart failure is the leading cause of an increased cardiovascular mortality in both overt and subclinical hyperthyroidism. Subclinical hypothyroidism with TSH 5-10 mIU/L might be associated with a lower risk of all-cause mortality.
CONTEXT: Thyroid dysfunction has been associated with both increased all-cause and cardiovascular mortality, but limited data are available on mild thyroid dysfunction and cause-specific mortality. OBJECTIVE: The objective of the study was to examine the risk of all-cause mortality, major adverse cardiovascular events (MACEs), and cause-specific events in subjects with overt and subclinical thyroid dysfunction. DESIGN: This was a retrospective cohort study. SETTING AND PARTICIPANTS: Participants in the study were subjects who underwent thyroid blood tests, without prior thyroid disease, consulting their general practitioner in 2000-2009 in Copenhagen, Denmark. MAIN OUTCOME MEASURE: All-cause mortality, MACEs, and cause-specific events identified in nationwide registries were measured. RESULTS: A total of 47 327 (8.4%) deaths occurred among 563 700 included subjects [mean age 48.6 (SD ± 18.2) y; 39% males]. All-cause mortality was increased in overt and subclinical hyperthyroidism [age adjusted incidence rates of 16 and 15 per 1000 person-years, respectively; incidence rate ratios (IRRs) 1.25 [95% confidence interval (CI) 1.15-1.36] and 1.23 (95% CI 1.16-1.30)] compared with euthyroid (incidence rate of 12 per 1000 person-years). Risk of MACEs was elevated in overt and subclinical hyperthyroidism [IRRs 1.16 (95% CI 1.05-1.27) and 1.09 (95% CI 1.02-1.16)] driven by heart failure [IRRs 1.14 (95% CI 0.99-1.32) and 1.20 (95% CI 1.10-1.31)]. A reduction of all-cause mortality was observed in subclinical hypothyroidism with TSH of 5-10 mIU/L [IRR 0.92 (95% CI 0.86-0.98)]. CONCLUSIONS:Heart failure is the leading cause of an increased cardiovascular mortality in both overt and subclinical hyperthyroidism. Subclinical hypothyroidism with TSH 5-10 mIU/L might be associated with a lower risk of all-cause mortality.
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: Layal Chaker; Christine Baumgartner; M Arfan Ikram; Abbas Dehghan; Marco Medici; W Edward Visser; Albert Hofman; Nicolas Rodondi; Robin P Peeters; Oscar H Franco Journal: Eur J Epidemiol Date: 2014-09-02 Impact factor: 8.082